Drugs / sonepcizumab
sonepcizumab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT01334255 | Mar 2011 → Feb 2012 | retinal detachment | Lpath, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00767949 | Oct 2008 → Jul 2010 | wet macular degeneration | Lpath, Inc. | Unknown | Met primary |
| Phase 1 | NCT00661414 | Apr 2008 → Dec 2011 | cancer | Lpath, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01762033 | Feb 2013 → Sep 2015 | renal cell carcinoma | Lpath, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01414153 | Aug 2012 → May 2015 | wet macular degeneration | Lpath, Inc. | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-12-02 | Pfizer | Lpath Completes Enrollment in its Phase 2 Clinical Trial of iSONEP for Wet Age-Related Macular Degeneration pfizer.com ↗ |
| 2011-10-05 | Pfizer | Lpath Granted Two Additional U.S. Patents Related to iSONEP and ASONEP Drug Programs pfizer.com ↗ |
| 2011-09-09 | Pfizer | Lpath Initiates Dosing of iSONEP in First of Two Proof-ofConcept Trials pfizer.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sonepcizumab | “ASONEP™ (sonepcizumab/LT1009) is a humanized monoclonal antibody that possesses anti-angiogenic and anti-tumor activity in animal models of human cancer.” NCT00661414 ↗1“iSONEP (sonepcizumab/LT1009)” NCT01334255 ↗ |
| Known as | ASONEP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01762033 ↗ |
| Known as | iSONEP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01414153 ↗ |
| Known as | LT1009 | “ASONEP™ (sonepcizumab/LT1009) is a humanized monoclonal antibody that possesses anti-angiogenic and anti-tumor activity in animal models of human cancer.” NCT00661414 ↗1“iSONEP (sonepcizumab/LT1009)” NCT01334255 ↗ |
| Known as | Sphingomab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109570 ↗ |
| Action | Inhibit | “demonstrate the potential of an anti-S1P treatment to reduce tumor volumes and metastatic potential, likely as a result of inhibiting new blood vessel formation needed to...” NCT00661414 ↗ |
| Modality | Monoclonal antibody | “ASONEP™ (sonepcizumab/LT1009) is a humanized monoclonal antibody” NCT00661414 ↗ |
| Route | Intravenous | “single intravenous (iv) use administered over 90 minutes” NCT00661414 ↗ |